Jayson Rieger
Known title: CEO and PresidentCIK: 0002043558
Jayson Rieger's purchase track record
Jayson Rieger has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2026 | VRCA | $126K | pending | pending | — |
| 11/25/2025 | VRCA | $400K | +9.2% | +17.6% | +11.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VRCA | ▲ Buy | Open Market | 5,000 | $25K | 8/17/2026 | View on chart |
| VRCA | ▲ Buy | Open Market | 20,000 | $101K | 8/14/2026 | View on chart |
| VRCA | ▲ Buy | Open Market | 94,311 | $400K | 11/25/2025 | View on chart |
| VRCA | ▼ Sell | Gift | 50,000 | $0 | 11/26/2024 | View on chart |
| VRCA | ▲ Buy | Open Market | 280,898 | — | 11/22/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Verrica to present new YCANTH data at dermatology conferences
Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.
Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.